CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple Turns 50: From Garage Startup to AI Crossroads 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
AUSTIN, Texas, Sept. 06, 2017 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the BioCentury 24th Annual Newsmakers in the Biotech Industry conference, being held September 8th at the Millennium Broadway Hotel in New York City.
Presentation Details:
Date: Friday, September 8
Time: 2:00pm Eastern Time
Location: The Millennium Broadway Hotel, Presentation Room 311
Webcast: http://www.wsw.com/webcast/biocentury4/mtem/index.aspx
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact: Andrew McDonald, Ph.D. [email protected] 646-597-6987
